• Subscribe
  • Magazine
  • Past Issues
  • Surveys
  • Industry Statistics
  • About Us
  • Members Only
  • Best Places to Work
    • Recent Quotes
    My Watchlist
    Indicators
    PennEnergy Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Otsuka Holdings Company ADR (OP: OTSKY )

    28.43 -0.39 (-1.35%)
    Streaming Delayed Price Updated: 3:50 PM EDT, Sep 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 24,944
    Open 28.45
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 28.82
    Today's Range 28.37 - 28.53
    52wk Range 16.04 - 31.14
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q2 2024
    Otsuka Holdings just reported results for the second quarter of 2024. 
    Via InvestorPlace
    OTSKY Stock Earnings: Otsuka Holdings Reported Results for Q1 2024
    Otsuka Holdings just reported results for the first quarter of 2024. 
    Via InvestorPlace

    Performance

    YTD
    +52.69%
    +52.69%
    1 Month
    +5.10%
    +5.10%
    3 Month
    +42.94%
    +42.94%
    6 Month
    +39.91%
    +39.91%
    1 Year
    +53.10%
    +53.10%

    More News

    Read More
    IGC Pharma Says Cannabinoid-Based Drug Candidate Provides Fast Relief With Fewer Side Effects For Alzheimer's-Associated Agitation
    Via Benzinga
    Alzheimer's-Focused Small Cap Firm IGC Pharma Releases Data, Candidate Reduces Agitation Compared To Placebo
    Via Benzinga
    Regulatory Setback For Medtronic's High Blood Pressure Device - FDA Backed Japanese Firms' Similar Device For Uncontrolled Hypertension
    Via Benzinga
    Exposures Product Safety
    Akebia's Anemia Drug Disappoints In Mid-Stage COVID-19 Study
    Via Benzinga
    Why Are Akebia Therapeutics Shares Falling Today?
    Via Benzinga
    FDA Rejects Akebia Therapeutics' Vadadustat For CKD-Associated Anemia
    Via Benzinga
    Individuals With Uncontrolled Hypertension - FDA Adcomm Panel Just Supported Japanese MedTech's Blood Pressure Treatment Device
    Via Benzinga
    Exposures Product Safety
    Japan's Otsuka Pharma-Lundbeck Partnered Depression Drug Gets FDA Approval For Alzheimer's Agitation
    Via Benzinga
    Targeting Autosomal Dominant Polycystic Kidney Disease With Novel Approaches
    Via Benzinga
    The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
    Via Benzinga
    Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
    Via Talk Markets
    4 Pre-Merger SPACs to Buy That Are Poised to Soar
    Via InvestorPlace
    Topics Electric Vehicles
    Exposures Electric Vehicles
    Akebia Therapeutics Stock Jumps as FDA Accepts Vadadustat US Application in CKD-Related Anemia
    Via Benzinga
    Exposures Product Safety
    3 Cheap Pharmaceutical Stocks to Grab Now
    Via Talk Markets
    Exposures COVID-19
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.